Control of hepatitis B in China: prevention and treatment

Wang, Yu; Jia, Jidong

doi:10.1586/eri.10.143

Cited by 36 publications

(33 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Soon afterward, the Chinese government introduced the hepatitis B vaccine into routine vaccination programs nationwide. Furthermore, in 2002, the HBV vaccination was integrated into the Expanded Program on Immunization, and a free hepatitis B vaccine was available to all neonates, with families required to pay only a small service fee [21]. In 2005, the Chinese government began providing completely no-cost HBV vaccination for all newborn infants at no charge to their families.…”

Section: Discussionmentioning

confidence: 99%

Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study

Wang¹,

Yu-Hui²,

Tao

et al. 2018

BMC Public Health

View full text Add to dashboard Cite

BackgroundViral hepatitis, mainly hepatitis B and C, is a serious public health problem worldwide. In China, the prevalence of hepatitis B virus (HBV) infection remains high, while that of hepatitis C virus (HCV) infection is controversial. This study investigated the epidemiology of HBV and HCV infections and assessed the beneficial effect of the vaccination strategy for hepatitis B in Northeastern China.MethodsFrom June 2016 to August 2016, 6541 residents of Changchun in Northeastern China were recruited for this cross-sectional study. Demographic characteristics as well as HBV and HCV serological test results were reviewed and analyzed.ResultsAmong all study participants, 3.8% and 0.36% tested positive for hepatitis B surface antigen (HBsAg) and anti-HCV, respectively. The HBsAg- and anti-HCV-positive rates were significantly higher in male participants (4.58% and 0.43%) than in female individuals (3.0% and 0.33%). Notably, among all age groups, the lowest rate of HBsAg positivity (0.2%) was found in children born after the implementation of the vaccination strategy for hepatitis B. Conversely, participants aged 40–49 years had significantly greater positive rates of HBsAg (5.9%) compared with those of other age groups. Furthermore, the highest rates of anti-HCV positivity (1.1%) were observed in participants aged 50–59 years.ConclusionsThe rate of HBsAg-positivity declined significantly following successful implementation of the policy on hepatitis B vaccination, indicating a beneficial impact on the control of HBV infection. However, only a slight decrease was observed in the anti-HCV–positivity rate, identifying an area in need of improvement within viral hepatitis prevention and control programs in China.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study

Wang¹,

Yu-Hui²,

Tao

et al. 2018

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…10 In 2005, a new vaccination regulation abolished all charges and user fees for all nationally recommended vaccines, including the hepatitis B in China. 11,12 These HBV immunization strategies were regarded as successful methods and have resulted in reduced HBsAg prevalence among children under 5 years old to less than 1% and prevented an estimated 16~20 million additional HBV carriers. 8 Also, these strategies have been estimated to achieve a cost-effectiveness of 1:51.…”

Section: Introductionmentioning

confidence: 99%

Strategy vaccination against Hepatitis B in China

Liao

Liang²

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Hepatitis B (HB) is a serious public health problem in China. Up to now, the hepatitis B virus (HBV) vaccination was the most cost-effective way to prevent HBV infection. Since 1992, when the Chinese government prioritized implementing the HBV vaccinations for newborns, China began to see a larger reduction in HBV infections. For children under 5 years, the prevalence of hepatitis B surface antigen (HBsAg) has decreased to 1.0%. However, many additional challenges for the prevention and control of HBV infection in China remain. There is a lack of knowledge of the significant impact of the HBV vaccination for the general public with 93 million HBV carriers and chronic HBV patients as infection sources. Therefore, the HBV vaccine application should focus on the optimization of immunization strategies according to HBV prevalence characteristics, improve the public's knowledge of HBV vaccinations, and help to ensure the protective effects of the HBV vaccine.

show abstract

“…Apart from lifestyle changes, many developing areas are undergoing rapid transition from communicable to noncommunicable disease. In China, 7% of people have chronic hepatitis B virus (HBV) infection as indicated by positive hepatitis B surface antigen (HBsAg) (Wang & Jia 2011).…”

Section: Introductionmentioning

confidence: 99%

Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes

Yang¹,

Wang²,

Luk³

et al. 2012

Endocrine-Related Cancer

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection promotes hepatocellular carcinoma (HCC) risk.In type 2 diabetes (T2D), use of insulin and statins was associated with reduced cancer risk while co-presence of low LDL cholesterol (LDLC !2.8 mmol/l) plus low triglyceride (TG; !1.7 mmol/l) increased cancer risk. There is experimental evidence showing that insulin insufficiency might promote HCC. In this study, we examined whether this lipid subphenotype and use of insulin or statins might modify the promoting effect of chronic HBV infection (indicated by the presence of hepatitis B surface antigen) on HCC. We analyzed data of 1319 T2D patients enrolled into the Hong Kong Diabetes Registry from December 1996 to January 2005 and followed up to 2005. Additive interaction was estimated using relative excess risk due to interaction and attributable proportion due to interaction. During 5782 person-years of follow-up, 1.74% (nZ23) of patients developed HCC (incidence, 3.98; 95% confidence interval, 2.36-5.60/1000 person-years). HbA1c R7.0% and the lipid phenotype (LDLC !2.8 mmol/l plus TG !1.7 mmol/l) increased the hazard ratios (HRs) of chronic HBV infection for HCC from 3.74 to 74.96 and from 11.01 to 89.82 respectively with significant interactions. Use of insulin or statins decreased the HRs from 37.51 to 5.87 and from 64.94 to 16.99 respectively with significant interactions (all P values !0.05). These findings support our hypothesis that hyperglycemia and co-presence of low LDLC plus low TG might enhance, while insulin or statin usage might attenuate the promoting effect of chronic HBV infection on HCC in T2D.

show abstract

Control of hepatitis B in China: prevention and treatment

Cited by 36 publications

References 18 publications

Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study

Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study

Strategy vaccination against Hepatitis B in China

Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes

Contact Info

Product

Resources

About